A Phase 1 interventional study of Bexagliflozin and Digoxin in Type2 Diabetes Mellitus, sponsored by Theracos. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-23.
Sponsored by Theracos · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Bexagliflozin · Diabetes Mellitus, Type 2.
Among the 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 3 that started in 2017, is one of 7 in phase 1, and was the 11th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Baylor Research Institute · Sites in United States
Ages 18–84
By country, each count listing its studies:
Bexagliflozin: first FDA approval 2023 (BRENZAVVY). What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 64 across the 15 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 15 have an industry lead sponsor. The 3 most frequent:
Theracos is the lead sponsor of 21 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 9 (100%) have results posted.
17 studies in Diabetes Mellitus, Type 2 by Theracos: none open now, none under way, none of them phase 3. Of 16 finished, 16 (100%) have results posted.
Among the 17 studies in Diabetes Mellitus, Type 2 by Theracos, this one is the 14th largest by enrollment, is one of 5 that started in 2017, is one of 9 in phase 1, and was the 13th registered.
Theracos’s Diabetes Mellitus, Type 2 studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Theracos’s 17 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the drug-drug interaction in your body when given the study drug, bexagliflozin, with the heart failure medication digoxin. The study will evaluate whether bexagliflozin effects the amount of digoxin in your blood and how safe the study drug is and how well the study drug is tolerated when taken with digoxin.
This was a phase 1, single center, open-label, two-period, two-treatment, crossover study to evaluate the effect of bexagliflozin tablets, 20 mg, on the pharmacokinetics (PK) of digoxin, 0.5 mg after co-administration in healthy subjects. Each subject was randomized into one of 2 treatment groups and participated in 2 treatment periods as outlined below. During the duration of the study, each subject received 8 single doses of bexagliflozin and 2 single doses of digoxin. Clinical laboratory tests and safety monitoring were conducted during Periods 1 and 2.
Group 1 - Period 1, Treatment A Subjects were admitted to the clinic on Day 0. Subjects received daily oral doses of a bexagliflozin tablet, 20 mg, starting on Day 1 for 8 days, and a single oral dose of 0.5 mg digoxin (two 0.25 mg tablets) was co-administered with bexagliflozin on Day 3. Blood samples for PK were drawn at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (h) on Day 3, 24 h (Day 4), 48 h (Day 5), 72 h (Day 6), 96 h (Day 7), and 120 h (Day 8) after administration of digoxin. Subjects were discharged on Day 8.
Group 1 - Period 2, Treatment B Subjects were admitted to the clinic on Day 18. On Day 19, subjects received a single oral dose of 0.5 mg digoxin. Blood samples for PK were drawn at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 h on Day 19, 24 h (Day 20), 48 h (Day 21), 72 h (Day 22), 96 h (Day 23), and 120 h (Day 24) after administration of digoxin. Subjects were discharged on Day 24.
Group 2 - Period 1, Treatment B Subjects were admitted to the clinic on Day 0. On Day 1, subjects received a single oral dose of 0.5 mg digoxin. Blood samples for PK were drawn at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 h on Day 1, 24 h (Day 2), 48 h (Day 3), 72 h (Day 4), 96 h (Day 5), and 120 h (Day 6) after administration of digoxin. Subjects were discharged on Day 6.
Group 2 - Period 2, Treatment A Subjects were admitted to the clinic on Day 14. Subjects received daily oral doses of a bexagliflozin tablet, 20 mg, for 8 days starting on Day 15, and a single oral dose of 0.5 mg digoxin (two 0.25 mg tablets) was co-administered with bexagliflozin on Day 17. Blood samples for PK were drawn at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 h on Day 17, 24 h (Day 18), 48 h (Day 19), 72 h (Day 20), 96 h (Day 21), and 120 h (Day 22) after administration of digoxin. Subjects were discharged on Day 22.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Digoxin
Drug: Bexagliflozin · Drug: Digoxin
Bexagliflozin tablets, 20 mg
Also known as: EGT0001442, EGT0001474
2 0.25 mg Digoxin tablets (total dose 0.5 mg digoxin)
Digoxin Cmax (Maximum Observed Plasma Concentration)
Blood samples for pharmacokinetic parameters were drawn at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 h after administration of digoxin
Time frame: Up to 120 hours
Digoxin Tmax (Time of Maximum Observed Plasma Concentration)
Blood samples for pharmacokinetic parameters were drawn at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 h after administration of digoxin
Time frame: Up to 120 hours
Digoxin T1/2 (Apparent Terminal Elimination Half-life)
Blood samples for pharmacokinetic parameters were drawn at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 h after administration of digoxin
Time frame: Up to 120 hours
AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)
Blood samples for pharmacokinetic parameters were drawn at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 h after administration of digoxin
Time frame: Up to 120 hours
| Milestone | Digoxin and Bexagliflozin Tablet, Then Digoxin Alone | Digoxin, Then Digoxin and Bexagliflozin |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 9 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
Blood samples for pharmacokinetic parameters were drawn at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 h after administration of digoxin
| ng/mL | Digoxin Alone | Digoxin With Bexagliflozin |
|---|---|---|
| Digoxin Cmax (Maximum Observed Plasma Concentration) | 2.315 ± 28.8 | 2.301 ± 40.9 |
Blood samples for pharmacokinetic parameters were drawn at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 h after administration of digoxin
| hours | Digoxin Alone | Digoxin With Bexagliflozin |
|---|---|---|
| Digoxin Tmax (Time of Maximum Observed Plasma Concentration) | 1.00 (1 to 2) | 1.00 (1 to 4) |
Blood samples for pharmacokinetic parameters were drawn at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 h after administration of digoxin
| hours | Digoxin Alone | Digoxin With Bexagliflozin |
|---|---|---|
| Digoxin T1/2 (Apparent Terminal Elimination Half-life) | 34.3 ± 15.5 | 38.2 ± 15.7 |
Blood samples for pharmacokinetic parameters were drawn at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 h after administration of digoxin
| h*ng/mL | Digoxin Alone | Digoxin With Bexagliflozin |
|---|---|---|
| AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity) | 35.558 ± 16.6 | 37.805 ± 27.5 |
Collected over Adverse event data were collected from Day 0 up to Day 24 of the study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Digoxin Alone | 0/20 (0%) | 0/20 (0%) | 3/20 (15%) |
| Digoxin With Bexagliflozin | 0/19 (0%) | 0/19 (0%) | 5/19 (26.3%) |
| Event | Digoxin Alone | Digoxin With Bexagliflozin |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/20 | 1/19 |
| Urinary tract infectionInfections and infestations | 0/20 | 1/19 |
| FatigueGeneral disorders | 0/20 | 1/19 |
| PalpitationsCardiac disorders | 0/20 | 1/19 |
| NauseaGastrointestinal disorders | 1/20 | 1/19 |
| ExcoriationInjury, poisoning and procedural complications | 0/20 | 1/19 |
| HypoglycemiaMetabolism and nutrition disorders | 0/20 | 1/19 |
| DizzinessNervous system disorders | 0/20 | 1/19 |
| Medical device site reactionGeneral disorders | 1/20 | 0/19 |
| Vision blurredEye disorders | 1/20 | 0/19 |
Safety population includes subjects dosed with any study drug.
| Age, Continuous(years) | Bexagliflozin and Digoxin, Then Digoxin Alone | Digoxin Alone, Then Bexagliflozin and Digoxin | Total |
|---|---|---|---|
| Mean | 44.8 ± 8.84 | 35.2 ± 6.37 | 40.0 ± 8.97 |
| Sex: Female, Male(Participants) | Bexagliflozin and Digoxin, Then Digoxin Alone | Digoxin Alone, Then Bexagliflozin and Digoxin | Total |
|---|---|---|---|
| Female | 5 | 5 | 10 |
| Male | 5 | 5 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Bexagliflozin and Digoxin, Then Digoxin Alone | Digoxin Alone, Then Bexagliflozin and Digoxin | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 7 | 12 |
| Not Hispanic or Latino | 5 | 3 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Bexagliflozin and Digoxin, Then Digoxin Alone | Digoxin Alone, Then Bexagliflozin and Digoxin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 6 |
| White | 6 | 7 | 13 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Weight(kg) | Bexagliflozin and Digoxin, Then Digoxin Alone | Digoxin Alone, Then Bexagliflozin and Digoxin | Total |
|---|---|---|---|
| Mean | 73.6 ± 11.28 | 74.2 ± 13.67 | 73.9 ± 12.20 |
| Height(cm) | Bexagliflozin and Digoxin, Then Digoxin Alone | Digoxin Alone, Then Bexagliflozin and Digoxin | Total |
|---|---|---|---|
| Mean | 167.1 ± 8.44 | 165.6 ± 9.35 | 166.4 ± 8.71 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2017 to primary completion in Sep 2017, 1 month.
Results were first posted in Jul 2021, 3 years 9 months after primary completion.
Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 1 month is below that.
Counting every sponsor, half of 516 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bexagliflozin
Theracos